Drugs / DERENOFYLLINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00744341 | Feb 2009 → Jan 2010 | cardio-renal syndrome | Solvay Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00160134 | Jan 2005 → ? | congestive heart failure | Solvay Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DERENOFYLLINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL592435 ↗ |
| Known as | Derenofilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL592435 ↗ |
| Known as | SLV320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00744341 ↗ |
| Action | Inhibit | “an adenosine A1 receptor antagonist” PMID 19919976 ↗ Sep 20091“Adenosine A1 receptor antagonist” CHEMBL592435 ↗ |
| Modality | Small molecule | — CHEMBL592435 ↗ |
| Route | Intravenous | “iv SLV320” NCT00160134 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor antagonist” CHEMBL592435 ↗ |